Key PointsThe Gates Foundation's equity portfolio reflects the influence of Warren Buffett on Gates' investment style.The trust is invested primarily in predictable businesses trad

Key PointsIntel is working with big tech companies on semiconductor deals, but not all of them have led to major increases in sales and earnings.The company is banking on its found

Key PointsMany cryptocurrencies are priced lower than they were a year ago.XRP is still seeing some robust ETF inflows. Dogecoin is still trying to launch its latest bid to attract

Key PointsThe Schwab U.S. Dividend Equity ETF (SCHD) looks at balance sheet quality, dividend history, and yield in its selection process.The Vanguard Dividend Appreciation ETF (VI

Key PointsNvidia offers rapid growth at a comparably low valuation. The company now holds more than $80 billion in liquidity, which speaks to the stability of its balance sheet.It

Key PointsSome did better than others, however.We can single out two of the Big Four banks, and a prominent brokerage as stars of this year's tests.10 stocks we like better than Ba

Key PointsThe earnings test could cost you money if you're working while under your full retirement age (FRA).The government may garnish your checks to collect certain unpaid debts

Key PointsSpaceX just announced that it's issuing $20 billion in short-term unsecured notes.It's using the proceeds to pay off a bridge loan due next year.The company is burning th

On 24 June, Micot Pharma-B (02335.HK) officially listed on the Hong Kong Stock Exchange, becoming the first innovative drug company under Chapter 18A of the Hong Kong Listing Rules with a peptide core technology platform — the long-awaited “Hong Kong’s First Peptide Innovative Drug Stock.”On its first trading day, its stock price performed strongly, closing at HK$36.90, more than double the offering price of HK$18.20, with its market capitalization quickly surpassing HK$10 billion. Prior to listing, the Hong Kong public offering was oversubscribed by more than 1,000 times, and the international placement was also oversubscribed, reflecting a recovery in market appetite for differentiated innovative drugs.As Hong Kong's first listed peptide-innovative drug company, Micot Pharma has spent over a decade focusing on dual- and multi-functional peptide innovative drugs, building a peptide drug portfolio spanning kidney, metabolic, cardiovascular, and cerebrovascular diseases. The company has self-developed a comprehensive pipeline consisting of one core product and six key candidates, all seven of which have entered clinical stages, with six filing simultaneously in both the PRC and the U.S., making it the Chinese company with the most innovative peptide drugs in clinical stages.MT1013: A Differentiated Pipeline Recognized by International Academic Institutions, with a Clear Commercialization PathMicot Pharma's core product, MT1013, is a dual-target receptor agonist polypeptide that simultaneously targets the CaSR and the OGP receptor. It primarily targets chronic kidney disease-secondary hyperparathyroidism (CKD-SHPT), a common complication of chronic kidney disease. The global patient population is projected to reach 188 million by 2030, with the related drug market in Chinese Mainland valued at approximately RMB 5 billion. This condition is not merely an elevation of parathyroid hormone (iPTH), but a systemic issue involving calcium-phosphorus imbalance, abnormal bone metabolism, and increased cardiovascular risk.Current mainstream drugs, such as cinacalcet and etelcalcetide, primarily lower iPTH but still have limitations in areas including blood calcium reduction, gastrointestinal side effects, improvements in bone metabolism, and overall target achievement rates. MT1013's differentiation lies in its dual-target synergy: it lowers iPTH through CaSR receptor while promoting bone metabolism improvement through OGP-related mechanisms. It aims to simultaneously improve multiple indicators, including iPTH, blood calcium, blood phosphorus, and bone metabolism.According to Phase II head-to-head clinical data disclosed by the company, MT1013 demonstrated a 2.2- to 2.5-fold higher comprehensive target achievement rate for iPTH, serum calcium, and serum phosphorus compared with etelcalcetide, while also significantly reducing FGF23 levels, a biomarker directly linked to cardiovascular risk. At the same time, MT1013's clinical value has also received substantial recognition from leading international academic institutions. Its research data was accepted as a "Late-Breaking" at the American Society of Nephrology (ASN) Annual Meeting, the highest-level recognition for innovative therapies on the world's most influential academic stage in nephrology.Currently, MT1013's Phase III clinical trial has completed patient enrolment. The company expects to submit an NDA application in early 2027 and achieve commercialization in early 2028. In 2026, the company entered into an exclusive commercialization partnership agreement with Everest Medicines (stock code: 1952.HK), covering China and the Asia-Pacific region (excluding Japan). The total upfront and milestone payments could reach up to RMB 1.24 billion, with RMB 200 million already received.XTL6001: Not Just Another GLP-1, but an Extension into Cardio-Renal-Metabolic TerritoryIf MT1013 serves as the near-term commercialization milestone, XTL6001 would represent Micot Pharma's second growth driver. XTL6001 is the world's first and only GLP-1R/GCGR/MasR tri-target agonist to have received IND approvals in both the PRC and the U.S. Compared with traditional GLP-1 or GLP-1/GIP dual-target drugs, its differentiation goes beyond "three targets". By introducing MasR, it brings significant hepatic and renal protective advantages. Activation of this pathway exerts anti-inflammatory, anti-fibrotic, and vasodilatory effects that directly address key mechanisms in CKD progression. This naturally extends its indication from weight loss to CKD with proteinuria and other diseases, addressing the shortcomings of single-target GLP-1 drugs in renal benefits. Additionally, XTL6001 offers multiple metabolic regulatory functions such as fat reduction and muscle preservation, providing patients with an integrated treatment approach from body composition optimization to target organ protection.Its indications extend from weight loss to CKD with proteinuria, MASH, and other conditions, targeting the renal disease gaps that GLP-1 drugs cannot cover. Preclinical studies show that XTL6001 achieves a greater reversal of fatty liver than tirzepatide and can further reduce the urine albumin-to-creatinine ratio (UACR) by an additional 15%–20% compared with finerenone. According to the company disclosure, the Phase I clinical trial of XTL6001 has been completed.MT1002 and MT200605: First and Only in the WorldIn addition to MT1013 and XTL6001, Micot Pharma has also built two high-potential product candidates, MT1002 and MT200605, targeting stroke and coronary heart disease. These are among the most burdensome cardiovascular and cerebrovascular conditions globally, yet remain areas with a severe shortage of innovative treatments. MT1002 is a coagulation factor II and GP IIb/IIIa dual-target peptide antagonist, primarily designed for clinical needs in anticoagulation and anti-thrombosis. Using a single molecule, it could address the existing challenge of balancing bleeding and ischemia in multi-drug combination regimens. MT200605 targets acute ischemic stroke (AIS) through dual mechanisms of promoting nerve regeneration and scavenging oxygen-free radicals, thereby blocking the cascade of pathological damage after AIS via two pathways. MT1002 is currently in Phase II clinical trials in both the U.S. and the PRC, demonstrating good efficacy and safety across different patient populations and dose levels. Meanwhile, MT200605 has completed patient enrolment for Phase II clinical trials in the PRC, with Phase I clinical studies demonstrating favorable safety and tolerability profile.Dual Endorsement from State-Owned and Industrial Capital: A Clearer Commercialization PathMicot Pharma brought in Qiyuan Hong Kong, Everest Medicines, and Summit Capital as cornerstone investors for this IPO, creating a structure involving local government funds, industrial capital, and professional healthcare investment institutions. Among them, Qiyuan Hong Kong represents support from Shaanxi provincial state-owned capital; Summit Capital represents recognition from professional healthcare investment; and Everest Medicines carries the most direct industrial significance. Everest Medicines had already signed an exclusive commercialization agreement with the company for MT1013. Its participation as a cornerstone investor in this IPO signifies the relationship has been upgraded from a purely commercial partnership to a dual endorsement of "industrial collaboration + equity subscription."From the PRC to the World: An Integrated Platform for First-in-Class Peptide DrugsMicot Pharma's underlying capability lies in establishing an integrated drug R&D system that supports global First-in-Class drugs from molecular design to clinical translation, further extending into an end-to-end global industrial chain platform spanning discovery, development, and commercialization. This positions the company not merely as a single-pipeline Chapter 18A company, but as a peptide innovative drug enterprise with platform-based innovation, global regulatory registration, international clinical execution, and industrialization capabilities. The early success of MT1013 and XTL6001 underscores Micot Pharma's ability to "select the right targets and understand the disease" and demonstrates the coordinated execution capacity of its end-to-end platform.The IPO raised approximately HK$1.067 billion, with proceeds primarily allocated to core pipeline clinical development and registration, commercialization rollout, development of product candidates, and R&D of the peptide technology platform. With a huge potential market, strong backing from government and strategic shareholders, and ample IPO funding, Micot Pharma has established a solid foundation to progressively realize its clinical and commercial value over the coming years, while acting as a key driving force for Chinese peptide innovation to expand globally.-End-25/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

Key PointsOccidental Petroleum achieved its initial debt target level earlier this year. It expected to produce more than $1.2 billion in additional free cash flow this year at the

Key PointsTo reach gold’s current market value in two decades, Bitcoin would need to appreciate 16.8% per year. Gold has been a premier store of value for thousands of years, but B

Key PointsUber Technology's mobility and delivery businesses continue to do well.That's helped drive revenue and profit higher.The company's investments in autonomous vehicles has

Key PointsAlpha and Omega Semiconductor's advanced computing segment is growing at an impressive rate, but those gains are currently buried under weaker performances from its other

On June 18, 2026, the 2026 International Automotive and Supply Chain Expo (Hong Kong), also known as Auto HK, opened at AsiaWorld-Expo.During the expo, Dongfeng Motor Corporation, a Chinese automaker, held a brand strategy launch event, officially unveiling its " Skyward Sailing Plan " global expansion ambition aimed at strengthening its presence in Hong Kong and other right-hand-drive markets worldwide.Among those attending the event were Dr. Wingco Lo, a member of the National Committee of the Chinese People's Political Consultative Conference, chief chairman of the Auto HK organizing committee and president of the Chinese Manufacturers' Association of Hong Kong; Yu Xiao, chairman of the Auto HK organizing committee and vice chairman and president of the Hong Kong Chinese Enterprises Association; Tam Yiu-chung, secretary-general of the Hong Kong Coalition and vice chairman of the Chinese Association of Hong Kong and Macao Studies; and Liu Yan, deputy secretary-general of the China Association of Automobile Manufacturers.Dongfeng unveils "Setting Sail" global expansion strategyYou Zheng, Deputy President of Dongfeng Motor Corporation, said technological innovation would remain the company's key driver for international expansion. As Hong Kong has been serving as a strategic hub for Dongfeng's development in right-hand-drive markets, it supports the brand expansion into Southeast Asia, Australia and New Zealand, the Middle East and other regions.Under its "Skyward Sailing Plan”, Dongfeng said it would focus on three technology pillars: "Tianyuan Intelligence Plan" for smart mobility, "Pure Sky Zero-Carbon Plan" for low-carbon technologies, and "All-Domain Safety" to enhance vehicle safety.Under the blueprint, Dongfeng said it would invest more than 100 billion yuan ($14.8 billion) over the next five years to implement a three-stage international expansion plan covering exporting vehicles, establishing local production, and developing overseas industrial ecosystems. The company plans to launch 55 overseas-specific vehicle models, establish 6,000 service outlets, build 10 large-scale overseas production bases with localized manufacturing accounting for 50% of output, and establish five overseas research and development centers and two overseas financial platforms. Dongfeng also aims to increase the proportion of locally hired overseas employees to 70%. By 2030, the company aims to achieve global sales of 5 million vehicles, with the share of new energy vehicles exceeding 70% and the proportion of overseas sales reaching 40%.Four-brand lineup targets right-hand-drive marketsAt the exhibition, Dongfeng showcased vehicles from four brands covering mass-market, smart family, premium intelligent and off-road segments. The company said its existing right-hand-drive models under the mass-market brand will remain the core of its market strategy, while development of vehicles under the three other premium brands is being accelerated. Together with its Hong Kong flagship store and supporting service network, Dongfeng said it aims to strengthen its presence in right-hand-drive markets through an integrated product and after-sales strategy.Several dedicated right-hand-drive models under the mass-market brand, including the DONGFENG 007, DONGFENG VIGO and DONGFENG BOX, have already been launched in Hong Kong. The company said sales in Hong Kong during the first quarter of 2026 provided support for its expansion in mass-market right-hand-drive segments.Development of right-hand-drive models under the Epicland, Voyah and MHero brands is also progressing, with plans to respectively expand into smart family vehicles, premium luxury vehicles and professional off-road segments.Dongfeng also said its Hong Kong flagship store has come online, offering maintenance services for right-hand-drive vehicles, localized charging solutions and tailored financing services, while supporting the expansion of its dealer network in Southeast Asia to provide integrated sales and after-sales services for right-hand-drive customers.Agreements signed to expand low-carbon initiativesDuring the event, Dongfeng signed several cooperation agreements related to its Hong Kong market strategy. The company’s subsidiary Dongfeng Import & Export Corporation signed an agreement with Oriental Swan Motor Group Limited, the company’s sole agent in Hong Kong, covering an order for 3,000 vehicles in the Hong Kong market for 2026. The company also announced cooperation agreements with several industry partners covering infrastructure, aviation services, retail operations and equipment services, aimed at supporting the development of smart, low-carbon mobility solutions in Hong Kong.Dongfeng said it will continue to pursue its international expansion strategy under the principle of "In Global For Global," while working with global partners to expand its presence in overseas markets.Company：China Dongfeng Motor Industry Imp. & Exp. Co., Ltd.Email: wangzhenling@dfmc.com.cnWebsite: www.Dongfeng-global.com25/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

Key PointsCostco pays a small quarterly dividend, then a much larger special dividend every few years.The conditions are ripe for Costco's next special dividend announcement later

Key PointsMacy's reported comps increases in all of its brands in the first quarter.It's reduced its footprint and is becoming more efficient.Macy's trades at a P/E ratio of 10.10

Key PointsQuantum computing is one of Wall Street's most exciting addressable opportunities, which is why shares of IonQ, Rigetti Computing, and D-Wave Quantum have skyrocketed.Ins

Key PointsArk Invest bought more than 3 million shares of SpaceX on its IPO day.In recent trading sessions, SpaceX stock has been losing momentum -- falling closer to its IPO price

Key PointsThe stock market had a volatile start to 2026, but every major U.S. index is in the green, led by the Nasdaq-100. However, investors who bought the iShares Expanded Tech

Key PointsSpaceX has dropped 23% from its post-IPO high of $202 per share, but history says the stock will fall much further.Among the 15 largest IPOs since 2006, the average stock

Key PointsNew Fed Chair Kevin Warsh has wasted little time changing the narrative at America's foremost financial institution.The Iran-war-driven energy supply disruption has sent

Key PointsNetflix's valuation is beyond cheap for a high-margin growth stock.Some investors are viewing Netflix's acquisition attempts as a red flag.Netflix has a strong content pi

Key PointsSocial Security's trust fund that retirement benefits are paid from could run dry by 2032.At that point, benefits could be subject to a 22% cut.Congress has never allowed

Key PointsSpaceX's lockup period depends in part on its stock price. The bulk of SpaceX Early Release Eligible Shares will remain locked up until late October. Demand from exchange

Key PointsThe Warsh-led Fed appears unlikely to cut rates as President Trump wants.Without directly naming the president, the Fed pointed to the Iran war as a key cause of high inf

TradingKey - After the US market close on June 24, memory chip giant Micron Technology ( MU) reported its fiscal third-quarter 2026 financial results, completely reversing market pessimism regarding A

Key PointsOracle's cloud infrastructure segment is posting substantial growth.Management's decision to lay off workers and ramp up AI spending could translate into higher margins a

TradingKey - After the U.S. market close on June 24, after Micron Technology ( MU) released its earnings report, JPMorgan Chase ( JPM) immediately raised its price target from $550 to $1,540, maintain

TradingKey - Japanese and South Korean stocks surge 5% in a tsunami-like rally, with Kioxia and SK Hynix both skyrocketing over 12%.During the Asian trading session on June 25, Japanese and South Kore

Key PointsBloom Energy is at the forefront of addressing the considerable power demands created by artificial intelligence (AI) data centersIt's carving out a leading position in o